Revenue remains highly volatile with a 62.6% growth rate in 2026Q1, yet the company continues to struggle with negative operating margins of -7.2% due to excessive R&D spending.
| Sales/Revenue | 4.29M | 3.64M | 4.26M | 1.82M | 157K | 25.99M | 23.85M | 7.3M | 236K | 508K | 399K | 1.27M |
| Revenue Growth % | -9.79% | -14.62% | 134.56% | 1057.32% | -99.4% | 8.96% | 226.91% | 2991.53% | -53.54% | 27.32% | -68.63% | - |
| Cost of Goods Sold | 1.2M | 5.92M | 0 | 395K | 1.53M | 28.56M | 35.13M | 9.28M | 1.08M | 551K | 200K | 751K |
| COGS % of Revenue | - | 162.76% | - | 21.74% | 977.07% | 109.89% | 147.28% | 127.19% | 458.05% | 108.46% | 50.13% | 59.04% |
| Gross Profit | 3.09M | -2.28M | 4.26M | 1.42M | -1.38M | -2.57M | -11.28M | -1.98M | -845K | -43K | 199K | 521K |
| Gross Margin % | 72.07% | -62.76% | 100% | 78.26% | -877.07% | -9.89% | -47.28% | -27.19% | -358.05% | -8.46% | 49.87% | 40.96% |
| Gross Profit Growth % | - | -153.59% | 199.72% | 203.27% | 46.42% | 77.21% | -468.35% | -134.79% | -1865.12% | -121.61% | -61.8% | - |
| Operating Expenses | 62.05M | 65.18M | 262.66M | 320.31M | 20.99M | 26.76M | 32.56M | 37.69M | 28.35M | 26.3M | 12.31M | 6.33M |
| OpEx % of Revenue | - | 1791.15% | 6162.79% | 17628.23% | 13371.34% | 102.98% | 136.5% | 516.57% | 12013.14% | 5176.57% | 3084.71% | 498.03% |
| Selling, General & Admin | 22.13M | 26.91M | 30.8M | 28.91M | 9.44M | 15.38M | 20.79M | 24.14M | 18.5M | 14.74M | 6.67M | 3.57M |
| SG&A % of Revenue | - | 739.35% | 722.6% | 1591.3% | 6012.74% | 59.19% | 87.16% | 330.84% | 7841.1% | 2901.77% | 1671.68% | 280.58% |
| Research & Development | 41.12M | 44.2M | 50.43M | 42.37M | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| R&D % of Revenue | - | 1214.56% | 1183.22% | 2331.7% | 7358.6% | 43.62% | 46.46% | 167.39% | 4172.03% | 2274.8% | 1413.03% | 217.45% |
| Other Operating Expenses | -1000K | -5.92M | 181.43M | 249.02M | 0 | 19K | 685K | 1.34M | 0 | 0 | 0 | 0 |
| Operating Income | -58.96M | -67.46M | -258.4M | -318.88M | -22.37M | -29.33M | -43.83M | -39.67M | -28.11M | -25.79M | -12.11M | -5.81M |
| Operating Margin % | -1375.71% | -1853.92% | -6062.79% | -17549.97% | -14248.41% | -112.87% | -183.77% | -543.76% | -11913.14% | -5076.57% | -3034.84% | -457.08% |
| Operating Income Growth % | - | 73.89% | 18.97% | -1325.49% | 23.74% | 33.08% | -10.48% | -41.11% | -9.02% | -112.97% | -108.27% | - |
| EBITDA | -53.48M | -61.54M | -251.54M | -314.19M | -20.84M | -26.99M | -41.96M | -38.07M | -27.03M | -25.24M | -11.76M | -5.67M |
| EBITDA Margin % | -1247.71% | -1691.15% | -5901.85% | -17291.69% | -13271.34% | -103.88% | -175.94% | -521.74% | -11455.08% | -4968.11% | -2948.37% | -445.52% |
| EBITDA Growth % | 78.94% | 75.53% | 19.94% | -1407.92% | 22.81% | 35.67% | -10.24% | -40.81% | -7.12% | -114.54% | -107.59% | - |
| D&A (Non-Cash Add-back) | 5.49M | 5.92M | 6.86M | 4.69M | 1.53M | 2.34M | 1.87M | 1.61M | 1.08M | 551K | 345K | 147K |
| EBIT | -67.8M | -96.69M | -248.49M | -318.75M | -16.74M | -27.77M | -43.4M | -38.12M | -26.64M | -25.72M | -12.08M | -5.63M |
| Net Interest Income | -17.66M | -35.04M | -33.56M | -18.36M | -27K | -1.41M | -878K | 110K | 264K | -1K | -5K | -261K |
| Interest Income | 347K | 438K | 631K | 527K | 60K | 17K | 557K | 1.6M | 1.52M | 0 | 0 | 0 |
| Interest Expense | 17.98M | 35.48M | 34.19M | 18.89M | 87K | 1.43M | 1.44M | 1.49M | 1.26M | 1K | 5K | 261K |
| Other Income/Expense | -45.03M | -64.71M | -24.29M | -18.76M | 5.48M | 133K | -1M | 61K | 218K | -191K | 23K | -75K |
| Pretax Income | -104M | -132.17M | -282.68M | -337.64M | -16.89M | -29.2M | -44.84M | -39.61M | -27.9M | -25.98M | -12.09M | -5.89M |
| Pretax Margin % | -2426.43% | -3632.1% | -6632.66% | -18582.44% | -10758.6% | -112.36% | -187.98% | -542.93% | -11820.76% | -5114.17% | -3029.07% | -462.97% |
| Income Tax | 34K | 29K | 29K | -4K | 0 | 0 | 0 | 0 | 0 | 1K | 5K | 0 |
| Effective Tax Rate % | -0.03% | -0.02% | -0.01% | 0% | 0% | 0% | 0% | 0% | 0% | -0% | -0.04% | 0% |
| Net Income | -101.42M | -127.08M | -251.39M | -267.63M | -16.89M | -29.2M | -44.84M | -39.61M | -27.9M | -25.98M | -12.09M | -5.89M |
| Net Margin % | -2366.33% | -3492.31% | -5898.36% | -14729.06% | -10758.6% | -112.36% | -187.98% | -542.93% | -11820.76% | -5114.17% | -3029.07% | -462.97% |
| Net Income Growth % | 63.1% | 49.45% | 6.07% | -1484.44% | 42.15% | 34.88% | -13.19% | -41.99% | -7.38% | -114.96% | -105.23% | - |
| Net Income (Continuing) | -104.03M | -132.2M | -282.71M | -337.64M | -16.89M | -29.2M | -44.84M | -39.61M | -27.9M | -25.98M | -12.09M | -5.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 5.67M | 44.82M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.16 | -2.78 | -10.83 | -25.95 | -0.03 | -0.05 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| EPS Growth % | 84.82% | 74.33% | 58.27% | -88769.86% | 42.18% | 99.92% | -9.59% | -32.8% | 18.97% | -146.92% | -105.24% | - |
| EPS (Basic) | - | -2.78 | -10.83 | -25.95 | -0.03 | -0.05 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| Diluted Shares Outstanding | 652.02M | 457.57M | 23.22M | 10.31M | 578.47M | 578.47M | 677.65M | 656.11M | 613.67M | 463.07M | 532M | 532M |
| Basic Shares Outstanding | 652.02M | 457.57M | 23.22M | 10.31M | 578.47M | 578.47M | 677.65M | 656.11M | 613.67M | 463.07M | 532M | 532M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |
Liquidity and dilution risk
As reported in financial statements, CBUS revenue remains highly erratic, with a 62.6% growth rate in 2026Q1 following a 12.8% decline in 2025Q4, underscoring the company's reliance on non-recurring milestone payments rather than a stable, predictable royalty stream from its gene-editing trait platform.
The revenue profile suggests a business model that is currently project-based rather than commercialized. Investors should monitor whether the company can transition from one-time R&D service fees to recurring royalty revenue, as the current volatility indicates a lack of sustained market adoption for its proprietary RTDS technology.
Based on CBUS's reported figures, the company maintains a heavy R&D expenditure that consistently dwarfs its quarterly revenue, with R&D costs reaching $8.7M in 2026Q1 against only $1.7M in revenue, highlighting the significant capital intensity required to sustain its gene-editing platform development.
The cost structure appears heavily skewed toward long-term R&D, which is essential for platform viability but creates a massive disconnect with current commercial output. This expense discipline warrants further investigation, as the company's ability to scale revenue without a proportional increase in R&D remains unproven.
According to recent SEC filings, CBUS exhibits extreme operating leverage inefficiency, with operating margins consistently deep in negative territory, reaching -7.2% in 2026Q1, which reflects a structural inability to cover fixed laboratory and personnel costs with the current, limited revenue base.
The data suggests that the company has yet to achieve the necessary scale to leverage its fixed-cost base effectively. The persistent operating losses imply that the business model may require a significant increase in commercial trait licensing to reach a break-even point, which currently appears distant.
As indicated by the company's financial disclosures, the cash burn rate is alarmingly high relative to its $9.9M cash position, suggesting that the firm may face a critical liquidity shortfall within the next year unless it secures additional dilutive financing or strategic capital.
The disparity between the company's massive net losses and its limited cash reserves suggests that the current operational trajectory is unsustainable without external intervention. Investors should be wary of the potential for significant equity dilution, which may be necessary to fund the ongoing R&D requirements.
Quick answers to the most common questions about buying CBUS stock.
For fiscal year 2025, Cibus, Inc. (CBUS) reported total revenue of $3.6M. This represents a 186.1% increase compared to $1.3M in 2015.
Cibus, Inc. (CBUS) reported a net loss of $127.1M for the fiscal year ending 2025.
Cibus, Inc. (CBUS) reported an operating income of $-67.5M, resulting in an operating profit margin of -1853.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Cibus, Inc. (CBUS) generated $-2.3M in gross profit for the year, representing a gross profit margin of -62.8%. This demonstrates the company's core pricing power and production efficiency.